Professor David Gillatt is actively involved in research and clinical trials, and has a longstanding role (1998 to date) with the UK-based ProtecT (Prostate testing for cancer and Treatment) initiative and its associated studies ProMPT and ProDiet. These studies are examining the role of early detection and treatment for prostate cancer. This research will assist in the detection  of prostate cancer and whether early treatment is superior to delaying treatment and targeting only those progressing.

David is also involved in other trials including:

  • Robotics and surgery
  • Volatiles and cancer enhanced recovery in urology
  • VEGF sub-types and progression in urological cancers
  • Insulin-derived growth factors and prostate cancer•
  • Hormonal and genetic regulation of ethnic group-specific mechanism in prostate cancer.

David has published close to 300 peer-reviewed articles in the field of urology – primarily in the diagnosis and treatment of prostate cancer.